南方医科大学学报

南方医科大学学报 ›› 2022, Vol. 42 ›› Issue (8): 1182-1190.doi: 10.12122/j.issn.1673-4254.2022.08.10

• • 上一篇    下一篇

FNDC1在肺腺癌中高表达并与不良预后相关

洪海宁，朱浩楠，李 超，臧 超，桑海威，陈力维，王安生   

  1. 蚌埠医学院第一附属医院胸外科，安徽 蚌埠 233004；蚌埠医学院研究生院，安徽 蚌埠 233030
  • 出版日期:2022-08-20 发布日期:2022-09-05

FNDC1 is highly expressed in lung adenocarcinoma and closely related with poor prognosis

HONG Haining, ZHU Haonan, LI Chao, ZANG Chao, SANG Haiwei, CHEN Liwei, WANG Ansheng   

  1. Department of Thoracic Surgery, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China; Graduate School of Bengbu Medical College, Bengbu 233030, China
  • Online:2022-08-20 Published:2022-09-05

RichHTML

56

PDF

441

摘要： 目的 研究Ⅲ型纤连蛋白结构域1（FNDC1）蛋白在肺腺癌组织中的表达及临床意义。 方法 采用GEO数据库及GEPIA预 测FNDC1在肺腺癌的表达水平，进一步对92例肺腺癌组织及配对的相邻正常组织进行免疫组化染色，验证FNDC1的表达。分析FNDC1表达与肺腺癌患者临床特征之间的关系，使用Cox生存分析进一步研究其预后价值。 结果 GEO数据库及GEPIA结果显示，肺腺癌组织中FNDC1的表达水平高于其配对的正常组织（P<0.05）。Kaplan-Meier生存分析显示，FNDC1蛋白表达量较高的患者的总生存期较短（P=0.035，0.036，0.00029）。免疫组化结果显示，与正常肺组织相比，肺腺癌组织FNDC1蛋白表达水平升高（P<0.001）。FNDC1蛋白的高表达与临床分期（P=0.044）、T分期（P=0.047）、N分期（P=0.003）存在相关性。Cox单变量及多变量回归生存分析结果显示，FNDC1表达水平增加是肺腺癌患者预后不良的独立危险因素（P<0.05）。结论 FNDC1蛋白在肺腺癌患者中高表达且与肺腺癌的发生发展及预后密不可分，有可能成为判断肺腺癌患者生存预后的标志物。

关键词: 肺腺癌；FNDC1；生物信息学；免疫组化；预后

Abstract: Objective To explore the expression of fibronectin type III domain containing 1 (FNDC1) protein in lung adenocarcinoma and its prognostic significance. Methods The expression of FNDC1 in lung adenocarcinoma was predicted by analysis of data from GEO database and GEPIA, and the results were verified by immunohistochemical staining in 92 pairs of clinical specimens of lung adenocarcinoma and adjacent tissues. We further analyzed the correlation of FNDC1 expression with the clinicopathological features of the patients, and evaluated its prognostic value using Cox survival analysis. Results Analysis of the data form GEO database and GEPIA showed a significantly higher expression level of FNDC1 in lung adenocarcinoma than in matched normal tissues (P<0.05). Kaplan-Meier survival analysis suggested that a high expression of FNDC1 protein was associated with a significantly shorter overall survival time of the patients (P<0.05). Immunohistochemistry of the clinical specimens also showed a significantly higher protein expression of FNDC1 in lung adenocarcinoma tissues than in paired adjacent tissues (P<0.001). A high expression of FNDC1 protein was significantly correlated with advanced clinical stage, T stage and N stage (P<0.05). Cox univariate and multivariate regression survival analysis indicated that an increased expression of FNDC1 was an independent risk factor for poor prognosis of the patients with lung adenocarcinoma (P<0.05). Conclusion FNDC1 protein is highly expressed in patients with lung adenocarcinoma and in closely related with the occurrence, progression and prognosis of the tumor, suggesting the value of FNDC1 protein as a potential biomarker for assessment of the survival and prognosis of patients with lung adenocarcinoma.

Key words: lung adenocarcinoma; fibronectin type III domain containing 1; bioinformatics；immunohistochemistry; prognosis